Cell Surface Markers and their Targeted Drugs in Breast Cancer.

Yufei Ma, Weidong Li, Kai Ma, Tianyun Wang, Huigen Feng

Journal: Current protein & peptide science 2022;23(5):335-346

PMID: 35638536

Abstract

Breast cancer is the most common cancer affecting women's health, and its incidence rate is continuously increasing. With the development of immunohistochemistry and gene expression microarray technology, the study on breast cancer has gradually advanced, contributing to the development of targeted therapy for breast cancer. At present, the popular breast cancer cell surface markers includeG protein-coupled estrogen receptor 1 (GPER-1), human epidermal growth factor receptor 2 (HER-2), epidermal growth factor receptor (EGFR), c-mesenchymal-epithelial transition factor (CMet), folate receptor-α (FRα), integrin, programmed death-ligand 1 (PD-L1), trophoblast cell surface antigen 2 (Trop-2), etc. Targeted drugs for breast cancer cell surface markers mainly include antibody drugs and small molecule inhibitor drugs, which exert anti-tumor activity by targeting receptors or ligands. This review summarizes the surface markers of breast cancer cells and their targeted drugs, hoping to provide new ideas for breast cancer targeted therapy.

Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Address: School of Life Science and Technology, Xinxiang Medical University, Xinxiang, 453003, China.; International Joint Research Laboratory for Recombinant Pharmaceutical Protein Expression System of Henan, Xinxiang Medical University, Xinxiang, 453003, China.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.